Cargando…
Targeting immunometabolic pathways for combination therapy in Alzheimer's disease
The recent success of disease‐modifying anti‐amyloid monoclonal antibodies in slowing Alzheimer's disease (AD) symptoms has been an exciting step forward for the field. Despite successfully clearing amyloid from the brain, however, only modest symptomatic improvement has been demonstrated, and...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10541802/ https://www.ncbi.nlm.nih.gov/pubmed/37786483 http://dx.doi.org/10.1002/trc2.12423 |